Novartis AG ADR (NVS)vsPHAXIAM Therapeutics S.A. (PHXM)
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
PHXM
PHAXIAM Therapeutics S.A.
$3.10
0.00%
HEALTHCARE · Cap: $28.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 960449% more annual revenue ($57.36B vs $5.97M). NVS leads profitability with a 17.5% profit margin vs -191.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
PHXM
Avoid11
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Intrinsic value data unavailable for PHXM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -63.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : PHXM
The strongest argument for PHXM centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : PHXM
The primary concerns for PHXM are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while PHXM is a turnaround play — different risk/reward profiles.
PHXM carries more volatility with a beta of 1.96 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 11/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →PHAXIAM Therapeutics S.A.
HEALTHCARE · BIOTECHNOLOGY · USA
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. The company is headquartered in Lyon, France.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?